# A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

> **NCT06872125** · PHASE3 · RECRUITING · sponsor: **Stoke Therapeutics, Inc** · enrollment: 170 (estimated)

## Conditions studied

- Dravet Syndrome

## Interventions

- **DRUG:** zorevunersen
- **OTHER:** Sham Comparator

## Key facts

- **NCT ID:** NCT06872125
- **Lead sponsor:** Stoke Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2027-03
- **Final completion:** 2028-10
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06872125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06872125, "A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome". Retrieved via AI Analytics 2026-09-02 from https://api.ai-analytics.org/clinical/NCT06872125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*